25
Participants
Start Date
February 28, 2011
Primary Completion Date
September 30, 2012
Study Completion Date
September 30, 2012
ibalizumab (biologic/MAb) for SC Injection or placebo
ibalizumab or matching placebo administered by subcutaneous injection weekly at 120 mg
ibalizumab (biologic/MAb) for SC Injection or placebo
ibalizumab or matching placebo administered by subcutaneous injection weekly at 240 mg
ibalizumab (biologic/MAb) for SC Injection or placebo
ibalizumab or matching placebo administered by subcutaneous injection weekly at 480 mg
ACRIA - AIDS Community Research Initiative of America, New York
University of Rochester, Rochester
Research Access Network / The Schrader Clinic, Houston
Living Hope Clinical Foundation, Long Beach
Quest Clinical Research, San Francisco
Alabama Vaccine Research Center, Birmingham
Collaborators (1)
Aaron Diamond AIDS Research Center
OTHER
Bill and Melinda Gates Foundation
OTHER
TaiMed Biologics Inc.
INDUSTRY